Laboratory Testing for Bleeding Assessment
Order a complete blood count with platelet count, PT/INR, aPTT, and fibrinogen level as first-line tests to assess bleeding severity and coagulopathy 1.
Core Coagulation Panel
The essential laboratory workup should include:
- Platelet count - Critical for assessing thrombocytopenia as a cause of bleeding 1, 2
- Prothrombin time (PT) or INR - Evaluates extrinsic pathway and warfarin effect 1
- Activated partial thromboplastin time (aPTT) - Assesses intrinsic pathway defects 1
- Fibrinogen level (Clauss method preferred) - Essential for detecting hypofibrinogenemia and DIC 1, 3
These four tests form the standard coagulation assessment and should be obtained before any blood component transfusion in bleeding patients 1.
Additional First-Line Tests
Beyond the core panel, obtain:
- Complete blood count (CBC) with differential - Assesses hemoglobin/hematocrit to quantify bleeding severity and evaluate for anemia 2, 4
- Blood type and crossmatch - Essential if severe bleeding is present or anticipated 4
- Serum electrolytes, BUN, and creatinine - Evaluates volume status and renal function in bleeding patients 4
Second-Line Coagulation Studies
If initial testing is abnormal or clinical suspicion remains high despite normal screening tests, proceed with:
- D-dimer - Highly sensitive for DIC and fibrinolysis; elevated levels correlate with disease severity 1, 5
- Thrombin time - Detects fibrinogen abnormalities and heparin effect 1
- Platelet function testing - Indicated when platelet dysfunction is suspected (e.g., aspirin, clopidogrel use) or platelet count is adequate but bleeding persists 1, 6
- Factor assays (VIII, IX, XI for intrinsic pathway; II, V, VII, X for extrinsic pathway) - Performed when PT or aPTT is prolonged to identify specific factor deficiencies 2, 6
- von Willebrand factor testing - Most common inherited bleeding disorder; test when PT/aPTT are normal but bleeding history is significant 6, 7
Important caveat: PT and aPTT have remarkably poor sensitivity (1.0%-2.1%) for detecting clinically significant bleeding disorders in asymptomatic patients 8. These tests are most useful when there is active bleeding or strong clinical suspicion based on bleeding history.
Infection Assessment
For suspected infectious complications or sepsis-associated coagulopathy:
- Blood cultures - If fever, hemodynamic instability, or signs of sepsis are present
- White blood cell count with differential - Part of CBC, evaluates for leukocytosis or leukopenia
- Inflammatory markers (CRP, procalcitonin if available) - Support diagnosis of sepsis-induced coagulopathy 9
In sepsis-induced coagulopathy, expect thrombocytopenia and PT prolongation rather than hypofibrinogenemia, which distinguishes it from other DIC causes 9.
Autoimmune and Vasculitic Workup
When autoimmune or vasculitic etiology is suspected based on clinical presentation (systemic symptoms, rash, arthralgia, multi-organ involvement):
- Antinuclear antibody (ANA) - Screens for systemic autoimmune disease
- ANCA testing (c-ANCA/PR3 and p-ANCA/MPO) - Evaluates for ANCA-associated vasculitis 10, 11
- Complement levels (C3, C4) - Decreased in some vasculitides and autoimmune conditions
- Rheumatoid factor and anti-CCP antibodies - If rheumatoid arthritis suspected 12
- Lupus anticoagulant, anticardiolipin antibodies, anti-β2-glycoprotein I - For antiphospholipid syndrome if thrombosis accompanies bleeding 13
Specialized Testing for Specific Scenarios
For bone metabolism concerns (if fractures or bone pain present):
- Serum calcium, phosphorus, alkaline phosphatase
- 25-hydroxy-vitamin D and parathyroid hormone 2
For suspected inherited bleeding disorders:
- Factor XIII level
- Fibrinolysis assays (plasminogen, α2-antiplasmin)
- Genetic testing as second-line 6
For liver disease coagulopathy:
- Liver function tests (AST, ALT, bilirubin, albumin)
- Vitamin K trial if PT prolonged with normal aPTT 7
Critical Pitfalls to Avoid
Do not delay testing in active bleeding - Obtain platelet count immediately even if formal coagulation studies are pending; empiric platelet transfusion may be given if thrombocytopenia is suspected and bleeding is severe 1
INR is only validated for warfarin monitoring - Do not use INR targets to guide plasma transfusion in non-warfarin patients; this practice lacks evidence and causes harm 14
Normal PT/aPTT does not exclude bleeding disorders - von Willebrand disease and platelet function defects present with normal screening tests 6, 7
Avoid indiscriminate preoperative screening - PT/aPTT have minimal utility in asymptomatic patients without bleeding history 8
Distinguish thrombocytopenia causes - Platelet transfusion is ineffective and potentially harmful in immune-mediated destruction (ITP, TTP, HIT) 1, 15